within Pharmacolibrary.Drugs.ATC.L;

model L01CD51
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 9.6 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 205 / 1000000,
    adminCount     = 1,
    Vd             = 0.241,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Paclitaxel and encequidar is an orally administered combination product for cancer treatment. Paclitaxel is a microtubule inhibitor used in treatment of ovarian, breast, and other cancers. Encequidar is a P-glycoprotein inhibitor that increases the bioavailability of paclitaxel by inhibiting intestinal efflux, thereby enabling oral administration. The combination has received regulatory approval (e.g., FDA) for metastatic breast cancer in certain scenarios.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with advanced solid tumors; population PK analysis of oral paclitaxel with encequidar co-administration.</p><h4>References</h4><ol><li><p>Dai, MS, et al., &amp; Chao, TY (2023). Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study. <i>Therapeutic advances in medical oncology</i> 15 17588359231183680–None. DOI:<a href=&quot;https://doi.org/10.1177/17588359231183680&quot;>10.1177/17588359231183680</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37492633/&quot;>https://pubmed.ncbi.nlm.nih.gov/37492633</a></p></li><li><p>He, J, et al., &amp; Zhi, J (2022). Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 11(7) 867–879. DOI:<a href=&quot;https://doi.org/10.1002/psp4.12799&quot;>10.1002/psp4.12799</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35470967/&quot;>https://pubmed.ncbi.nlm.nih.gov/35470967</a></p></li><li><p>Ma, WW, et al., &amp; Jimeno, A (2022). A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. <i>Cancer chemotherapy and pharmacology</i> 90(1) 7–17. DOI:<a href=&quot;https://doi.org/10.1007/s00280-022-04443-1&quot;>10.1007/s00280-022-04443-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35731258/&quot;>https://pubmed.ncbi.nlm.nih.gov/35731258</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01CD51;
